Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Physiologic Mixed Meal Tolerance

Last updated: July 30, 2024
Sponsor: Stephanie B. Seminara, MD
Overall Status: Trial Not Available

Phase

1

Condition

Pregnancy

Healthy Volunteers

Treatment

Kisspeptin-10

mixed meal tolerance test

Clinical Study ID

NCT04532801
267337
  • Ages 18-40
  • Female
  • Accepts Healthy Volunteers

Study Summary

This study utilizes infusions of kisspeptin in healthy women to isolate the impact of kisspeptin on beta-cell responsivity assessed by the mixed meal tolerance test.

Eligibility Criteria

Inclusion

HISTORY

  • no personal history of chronic disease, except well controlled thyroid disease

  • no history of diabetes in a first degree relative, including gestational diabetes

  • no family or personal history of hyperlipidemia

  • normal timing of menarche (age 10-14)

  • normal menstrual cycles (q25-35 days)

  • no use of contraceptive pills, patches or vaginal rings within last 4 weeks

  • nulliparous (no history of a pregnancy)

  • no active illicit drug use

  • no history of a medication reaction requiring emergency medical care

  • no difficulty with blood draws

  • stable weight for previous three months

  • available for all parts of the study

PHYSICAL

  • body mass index (18.5-25)

  • systolic BP < 120mm Hg, diastolic < 80 mm Hg

  • normal waist circumference (less than 32 inches)

LABORATORY STUDIES: (per Massachusetts General Hospital reference ranges)

  • fasting LDL cholesterol less than 130 mg/dL

  • fasting triglycerides less than 150 mg/dL

  • normal hemoglobin

  • hemoglobin A1C < 5.7%

  • blood urea nitrogen, creatinine not elevated

  • AST, ALT not elevated

  • negative serum pregnancy test

Study Design

Treatment Group(s): 2
Primary Treatment: Kisspeptin-10
Phase: 1
Study Start date:
September 01, 2019
Estimated Completion Date:
December 21, 2024

Study Description

Assignment: each study subject serves as their own control, and will come in timed to their cycle. The order in which they undergo the kisspeptin or placebo arms is randomized and separated by greater than two weeks to minimize variability and study-specific effects.

Delivery of Interventions:

Prior to each visit, study subjects will be asked to:

  • eat at least 150 gm carbohydrates per day

  • refrain from strenuous exercise

On the day of the visit, study subjects will:

  • eat a standardized meal prepared by the metabolic kitchen in the clinical research center

  • be observed overnight to ensure a 12-hour fast

  • have an IV placed, for a 16 hour kisspeptin or placebo infusion

  • after the 12 hour fast, starting at 8 am in the morning will undergo a mixed meal tolerance test

Connect with a study center

  • Massachusetts General Hospital

    Boston, Massachusetts 02114
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.